EA201890471A1 - Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью - Google Patents

Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью

Info

Publication number
EA201890471A1
EA201890471A1 EA201890471A EA201890471A EA201890471A1 EA 201890471 A1 EA201890471 A1 EA 201890471A1 EA 201890471 A EA201890471 A EA 201890471A EA 201890471 A EA201890471 A EA 201890471A EA 201890471 A1 EA201890471 A1 EA 201890471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
substituted
pentaase
biodusability
macro
Prior art date
Application number
EA201890471A
Other languages
English (en)
Inventor
Джеффри Л. Кин
Отто Ф. Шалл
Деннис П. Райли
Original Assignee
ГАЛЕРА ЛЭБЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГАЛЕРА ЛЭБЗ, ЭлЭлСи filed Critical ГАЛЕРА ЛЭБЗ, ЭлЭлСи
Publication of EA201890471A1 publication Critical patent/EA201890471A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic System
    • C07F1/08—Copper compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/04—Nickel compounds
    • C07F15/045—Nickel compounds without a metal-carbon linkage

Abstract

Аспекты настоящего изобретения относятся к соединениям, которые имеют повышенную пероральную биодоступность. Комплексное соединение переходного металла содержит переходный металл, координированный макроциклом, содержащим 15-членное макроциклическое кольцо пентаазы, соответствующее формуле A, и два аксиальных лиганда, имеющих формулу OC(O)X.каждый из двух аксиальных лигандов имеет формулу OC(=O)X, где каждый Xпредставляет собой независимо замещенный или незамещенный фенил или C(-X) (-X) (-X); каждый Xпредставляет собой независимо замещенный или незамещенный фенил, или замещенный или незамещенный алкил; каждый Xнезависимо представляет собой водород, гидроксил, алкил, амино, -XC(=O)R, где Xпредставляет собой NH или O, а Rпредставляет собой C-Cалкил, замещенный или незамещенный арил или C-Cаралкил, или -OR, где Rпредставляет собой C-Cалкил, замещенный или незамещенный арил или C-Cаралкил, или вместе с Xпредставляет собой (=O); и каждый Xнезависимо представляет собой водород или вместе с Xпредставляет собой (=O).
EA201890471A 2015-08-11 2016-08-11 Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью EA201890471A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203761P 2015-08-11 2015-08-11
PCT/US2016/046599 WO2017027728A1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability

Publications (1)

Publication Number Publication Date
EA201890471A1 true EA201890471A1 (ru) 2018-10-31

Family

ID=57984526

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890471A EA201890471A1 (ru) 2015-08-11 2016-08-11 Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью

Country Status (29)

Country Link
US (5) US10597415B2 (ru)
EP (2) EP3334744B1 (ru)
JP (3) JP7041959B2 (ru)
KR (1) KR20180064380A (ru)
CN (3) CN113416170A (ru)
AU (3) AU2016306568B2 (ru)
CA (1) CA2994845A1 (ru)
CL (1) CL2018000371A1 (ru)
CO (1) CO2018002544A2 (ru)
CY (1) CY1123960T1 (ru)
DK (1) DK3334744T3 (ru)
EA (1) EA201890471A1 (ru)
ES (1) ES2807528T3 (ru)
HK (1) HK1257313A1 (ru)
HR (1) HRP20201092T1 (ru)
HU (1) HUE049926T2 (ru)
IL (3) IL297735B1 (ru)
LT (1) LT3334744T (ru)
MX (2) MX2018001605A (ru)
MY (1) MY196401A (ru)
PH (1) PH12018500296A1 (ru)
PL (1) PL3334744T3 (ru)
PT (1) PT3334744T (ru)
RS (1) RS60558B1 (ru)
SG (1) SG10202002859QA (ru)
SI (1) SI3334744T1 (ru)
UA (1) UA126788C2 (ru)
WO (1) WO2017027728A1 (ru)
ZA (2) ZA201801546B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056675B1 (en) 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
JP6267638B2 (ja) 2011-09-26 2018-01-24 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 疾患の治療方法
SG10202002859QA (en) 2015-08-11 2020-05-28 Galera Labs Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
CN109906081A (zh) 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
AU2018221043A1 (en) 2017-02-15 2019-09-12 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
IL269915B (en) 2017-04-13 2022-09-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
IL305082A (en) * 2017-04-13 2023-10-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
JP2022551494A (ja) * 2019-10-10 2022-12-09 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー マンガン含有配位錯体の水性製剤の製造方法、製剤および処置方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
KR0145953B1 (ko) 1991-07-19 1998-08-17 제임스 클리프튼 보올딩 슈퍼옥사이드의 불균화촉매로서 효과적인 질소를 포함하는 마크로사이클 릭리간드의 망간착물
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0756495A1 (en) 1994-04-22 1997-02-05 Monsanto Company Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
BR9610241A (pt) 1995-08-17 1999-06-29 Monsanto Co Processos para análise de imagem de diagnóstico utilizando bioconjgados de complexos de metal de ligandos macrocíclicos contendo nitrogênio
US5976498A (en) 1995-08-17 1999-11-02 Neumann; William L. Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
EP1045851B1 (en) 1997-11-03 2003-04-23 Duke University Substituted porphyrins
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
EP1185312B1 (en) 1999-05-27 2005-03-23 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
AU3679801A (en) 2000-02-08 2001-08-20 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
DE60233317D1 (de) 2001-01-19 2009-09-24 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002071054A1 (en) * 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
BRPI0213846B8 (pt) 2001-11-01 2021-05-25 Uab Research Foundation composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos
JP2005530738A (ja) 2002-04-16 2005-10-13 アイシス・イノヴェイション・リミテッド 組織障害の予防及び／又は治療のためのクルクミン
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
GB0412893D0 (en) * 2004-06-10 2004-07-14 Univ Hull Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
WO2006078713A2 (en) 2005-01-19 2006-07-27 Metaphore Pharmaceuticals, Inc. Methotrexate combinations for treating inflammatory diseases
CA2601575A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
US20100158857A1 (en) 2006-05-23 2010-06-24 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
US20080139525A1 (en) 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
EP2056675B1 (en) 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
WO2009065059A2 (en) * 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
WO2009111294A1 (en) 2008-02-29 2009-09-11 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
CA2720846A1 (en) 2008-04-15 2009-11-05 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
JP6267638B2 (ja) 2011-09-26 2018-01-24 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 疾患の治療方法
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
SG10202002859QA (en) 2015-08-11 2020-05-28 Galera Labs Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
BR112018072560A2 (pt) 2016-05-03 2019-02-19 Galera Labs, Llc terapia de combinação para tratamento do câncer

Also Published As

Publication number Publication date
US10597415B2 (en) 2020-03-24
ES2807528T3 (es) 2021-02-23
HK1257313A1 (zh) 2019-10-18
IL257346B (en) 2021-12-01
US11066433B2 (en) 2021-07-20
US9738669B2 (en) 2017-08-22
JP2018525388A (ja) 2018-09-06
HUE049926T2 (hu) 2020-11-30
KR20180064380A (ko) 2018-06-14
AU2020289730A1 (en) 2021-01-21
US9738670B2 (en) 2017-08-22
CL2018000371A1 (es) 2018-08-03
EP3334744A1 (en) 2018-06-20
CN108350009B (zh) 2021-07-09
PT3334744T (pt) 2020-07-28
JP2024012401A (ja) 2024-01-30
AU2016306568B2 (en) 2021-01-07
CN113416170A (zh) 2021-09-21
WO2017027728A1 (en) 2017-02-16
EP3334744A4 (en) 2019-03-06
AU2023200738A1 (en) 2023-03-09
CN108350009A (zh) 2018-07-31
DK3334744T3 (da) 2020-07-27
LT3334744T (lt) 2020-07-27
MY196401A (en) 2023-03-29
CO2018002544A2 (es) 2018-07-10
RS60558B1 (sr) 2020-08-31
ZA201801546B (en) 2020-07-29
CY1123960T1 (el) 2022-03-24
US20170044193A1 (en) 2017-02-16
SI3334744T1 (sl) 2020-10-30
EP3738967A1 (en) 2020-11-18
JP2022023183A (ja) 2022-02-07
IL287546A (en) 2021-12-01
ZA202001373B (en) 2021-10-27
US20180237462A1 (en) 2018-08-23
US20170042907A1 (en) 2017-02-16
IL287546B (en) 2022-12-01
EP3334744B1 (en) 2020-04-22
AU2020289730B2 (en) 2022-11-10
HRP20201092T1 (hr) 2020-10-30
SG10202002859QA (en) 2020-05-28
JP7041959B2 (ja) 2022-03-25
PL3334744T3 (pl) 2020-09-21
MX2018001605A (es) 2018-09-26
IL297735A (en) 2022-12-01
CA2994845A1 (en) 2017-02-16
IL257346A (en) 2018-03-29
IL297735B1 (en) 2024-04-01
CN113402560A (zh) 2021-09-17
WO2017027728A9 (en) 2017-04-06
US20210347796A1 (en) 2021-11-11
MX2022010230A (es) 2022-09-19
UA126788C2 (uk) 2023-02-08
IL287546B2 (en) 2023-04-01
US20200223879A1 (en) 2020-07-16
AU2016306568A1 (en) 2018-03-22
PH12018500296A1 (en) 2018-08-13

Similar Documents

Publication Publication Date Title
EA201890471A1 (ru) Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью
PH12021551167A1 (en) New heterocyclic compounds
UY37608A (es) Derivados de pirrolo[1,2-b]piridazina
EA201791584A1 (ru) Агрохимическая композиция
PH12020500673A1 (en) Compounds
AU2016277367A8 (en) Aryl sulfonohydrazides
MX2021015546A (es) Proceso para preparar 4-amino-piridazinas.
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
TR201909694T4 (tr) Janus kinaz (jak) inhibitörleri.
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
EA201691031A1 (ru) Синтез макроциклического трипептида, ингибирующего hcv ns3
MX2018003276A (es) Compuesto farmaceutico.
MX2015017156A (es) Inhibidores de bace.
MX2020014097A (es) Lipidos novedosos.
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
MX368882B (es) Proceso para la preparacion de triazinas.
MX2022002831A (es) Compuestos heterociclicos.
PH12015502851B1 (en) Curable composition
EA201170781A1 (ru) Дигидроэторфины и их получение
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
MX2022000243A (es) Nuevos compuestos heterociclicos.
MX2021004386A (es) Compuestos novedosos.
WO2014184272A3 (en) Chemical compositions for targeting isocitrate dehydrogenase and for treating cancer
EA201690924A1 (ru) Фторфенилпиразольные соединения